Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Zhejiang Starry Pharmaceutical Co.,Ltd. (603520.SS)
CNY9.76
+0.56 (+6.09%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
Xianju modern industrial cluster 317300
Xianju, CN
Xianju, CN
CEO
Weiyi Shen
Website
starrypharm.com
IPO
2016-03-09
ISIN CNE1000026N8
Description
Founded in 1997 and headquartered in Xianju, China, Zhejiang Starry Pharmaceutical Co.,Ltd. specializes in the research, production, and global distribution of X-CT non-ionic contrast agents and fluoroquinolone pharmaceuticals, along with their key intermediates. The company's extensive range of contrast agent products includes iohexol (and its hydrolysate and iodide derivatives), ioversol, iopamidol, iomeprol, iopromide, cybeclamine, iodixanol, gadopentetic acid dimeglumine, and glutamate. For fluoroquinolones, their offerings feature levofloxacin (and its hydrochloride salt), levoflurane, levofluorocarboxylic acid, pazufloxacin, and pazufloxacin mesylate.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY9.76
+0.56 (+6.09%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
31M
Beta
0.50
Float Shares
319.18M
Free Float %
72.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.73% | -4.42% | +9.48% | +15.65% | +1.88% | +26.60% | +37.10% | -28.61% | -72.24% | -21.35% | +86.52% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
9.76
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.39
Distress
Piotroski F-Score
6 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
2 / 5
Medium
ROA Score
3 / 5
Medium
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+4.0% Q1'26: +3.7% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+119.4% ★ Q1'26: +59.3% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-15.7% Q1'26: -19.3% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+2.7% Q1'26: +6.8% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+1.3% Q1'26: +2.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+7.2% Q1'26: -8.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×9.53× Q1'26: 15.83× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
695.66M
est: 696.00M (0.0%)
|
672.95M
est: 696.00M (-3.3%)
|
710.94M
est: 795.00M (-10.6%)
|
890.47M
est: 807.00M (+10.3%)
|
1.31B
est: 1.35B (-3.2%)
|
1.37B
est: 1.63B (-16.1%)
|
2.00B
est: 1.89B (+5.6%)
|
2.13B
est: 2.13B (+0.0%)
|
2.20B
est: 2.44B (-10.1%)
|
2.35B
est: 2.44B (-3.6%)
|
2.45B
est: 2.67B (-8.5%)
|
2.68B
2.68B – 2.68B
+0.2% YoY
|
2.91B
2.91B – 2.91B
+8.7% YoY
|
3.15B
3.15B – 3.15B
+8.4% YoY
|
| EBITDA |
189.37M
est: 146.23M (+29.5%)
|
189.05M
est: 146.23M (+29.3%)
|
211.86M
est: 167.03M (+26.8%)
|
269.67M
est: 169.55M (+59.1%)
|
416.95M
est: 284.05M (+46.8%)
|
523.69M
est: 342.39M (+53.0%)
|
624.88M
est: 397.95M (+57.0%)
|
189.93M
est: 447.72M (-57.6%)
|
333.56M
est: 387.48M (-13.9%)
|
264.23M
est: 386.60M (-31.7%)
|
311.24M
est: 423.72M (-26.5%)
|
424.51M
424.51M – 424.51M
+0.2% YoY
|
461.63M
461.63M – 461.63M
+8.7% YoY
|
500.34M
500.34M – 500.34M
+8.4% YoY
|
| EBIT |
131.60M
est: 86.44M (+52.2%)
|
123.69M
est: 86.44M (+43.1%)
|
139.51M
est: 98.73M (+41.3%)
|
184.99M
est: 100.22M (+84.6%)
|
307.98M
est: 167.90M (+83.4%)
|
397.46M
est: 202.39M (+96.4%)
|
471.44M
est: 235.23M (+100.4%)
|
31.10M
est: 264.65M (-88.2%)
|
154.01M
est: 178.97M (-13.9%)
|
45.35M
est: 178.56M (-74.6%)
|
65.06M
est: 195.71M (-66.8%)
|
196.07M
196.07M – 196.07M
+0.2% YoY
|
213.22M
213.22M – 213.22M
+8.7% YoY
|
231.10M
231.10M – 231.10M
+8.4% YoY
|
| Net Income |
68.94M
est: 90.96M (-24.2%)
|
76.12M
est: 90.96M (-16.3%)
|
83.12M
est: 125.25M (-33.6%)
|
93.68M
est: 111.83M (-16.2%)
|
170.33M
est: 231.72M (-26.5%)
|
238.73M
est: 336.09M (-29.0%)
|
323.75M
est: 413.05M (-21.6%)
|
-75.85M
est: -90.01M (+15.7%)
|
44.23M
est: 39.37M (+12.3%)
|
-49.10M
est: -26.30M (-86.7%)
|
10.23M
est: 300.06M (-96.6%)
|
127.14M
127.14M – 127.14M
-57.6% YoY
|
267.43M
267.43M – 267.43M
+110.3% YoY
|
425.26M
425.26M – 425.26M
+59.0% YoY
|
| SGA |
115.38M
est: 41.54M (+177.8%)
|
132.70M
est: 41.54M (+219.5%)
|
80.55M
est: 47.45M (+69.8%)
|
103.69M
est: 48.16M (+115.3%)
|
129.44M
est: 80.69M (+60.4%)
|
150.13M
est: 97.26M (+54.4%)
|
150.57M
est: 113.04M (+33.2%)
|
216.31M
est: 127.18M (+70.1%)
|
227.00M
est: 234.71M (-3.3%)
|
244.51M
est: 234.18M (+4.4%)
|
235.41M
est: 256.66M (-8.3%)
|
257.14M
257.14M – 257.14M
+0.2% YoY
|
279.63M
279.63M – 279.63M
+8.7% YoY
|
303.08M
303.08M – 303.08M
+8.4% YoY
|
| EPS |
0.28
est: 0.22 (+26.0%)
|
0.25
est: 0.22 (+12.5%)
|
0.25
est: 0.31 (-18.3%)
|
0.29
est: 0.27 (+6.1%)
|
0.51
est: 0.57 (-9.9%)
|
0.71
est: 0.82 (-13.6%)
|
0.94
est: 1.01 (-6.9%)
|
-0.22
est: -0.22 (+0.0%)
|
0.13
est: 0.09 (+44.8%)
|
-0.12
est: -0.06 (-100.0%)
|
0.02
est: 0.69 (-96.6%)
|
0.29
0.29 – 0.29
-58.0% YoY
|
0.61
0.61 – 0.61
+110.3% YoY
|
0.97
0.97 – 0.97
+59.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-222.57M
OE per share TTM
-0.50
Owner's Yield
-4.19%
Maintenance CapEx ratio
125.49%
Maint CapEx / Avg PPE
111.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 12 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 178.0K | 0.39% |
| 2 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 9.1K | 0.26% |
| 3 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 4.0K | 0.48% |
| 4 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 449.5K | 0.06% |
| 5 | Dimensional - Emerging Markets Value ETF DFEV | 0.00% | 3.7K | 0.46% |
| 6 | Vanguard FTSE Global All Cap ex Canada Index ETF VXC.TO | 0.00% | 722.45 | 0.22% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 2.2K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 1.2K | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 515.12 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 59.55 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
35.3K
Shares Outstanding
438.41M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Chaoyang Yao | Deputy General Manager | — | male |
| Chun Ye | Deputy General Manager | — | male |
| Junfeng Guo | Secretary & Chief Financial Officer | — | male |
| Weiyi Shen | Vice Chairman & GM | — | male |
| Wentao Huang | Accounting Supervisor | — | — |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 603520.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
